Skip to Main Content
Prostate, Phase II

Carboplatin Chemotherapy before Surgery for Patients with High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

What is the purpose of this trial?

This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer who have inherited BRCA1 or BRCA2 gene mutations. This study selects a patient population in which carboplatin is more likely to work. The purpose of the study is to treat men with BRCA1 or BRCA2 mutations who are at higher risk of prostate cancer after surgery (removal of the prostate) compared to patients without these mutations. Carboplatin works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping, or slowing the growth of tumor cells. Giving carboplatin before surgery may shrink tumor in patients with high-risk prostate cancer who have BRCA1 and BRCA2 gene mutations.

Contact Information

For more information about this study, including how to volunteer, contact Joseph Kim

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

  • Last Updated
    04/28/2024
  • Study HIC
    #2000036263